Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 3, 2000, Pages 319-321

  Patt, Yehuda Z ^a,b   Hassan, Manal M ^a,b   Lozano, Richard D ^a,b   Ellis, Lee M ^a,b   Peterson, J Andrew ^a,b   Waugh, Kimberly A ^a,b   Buzdar, Aman U ^a,b   Wogan, Christine F ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b University of Texas M D Anderson Cancer Center ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Thalidomide

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; IRINOTECAN; METHYLPHENIDATE; MITOMYCIN C; RECOMBINANT ALPHA2B INTERFERON; THALIDOMIDE;

AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DROWSINESS; DRUG EFFICACY; HUMAN; LIVER CELL CARCINOMA; MALE;

ADMINISTRATION, ORAL; AGED; ALPHA-FETOPROTEINS; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; THALIDOMIDE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0034444007     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200006000-00023     Document Type: Article

References (14)

1. Isolation of a tumor factor responsible for angiogenesis
2. Induction of anglogenesis during the transition from hyperplasia to neoplasia
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
4. Adriamycin therapy in American patients with hepatocellular carcinoma
5. A phase II study of Adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States
6. Chemotherapy studies in primary liver cancer: A prospective randomized clinical trial
7. Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy
8. Durable clinical and pathological response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon a 2b, doxorubicin, and 5-fluorouracil
9. A resected case of hepatocellular carcinoma effectively treated by hepatic artery embolization and systemic chemotherapy
10. Thalidomide is an inhibitor of angiogenesis
11. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
12. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
13. Antitumor effect of angiogenesis inhibitor TNP-470 on human digestive organ malignancy
14. Early trials of anti-angiogenic agents